Table 2 Patient characteristics and response to trastuzumab
NEO setting n (%) | MTS setting n (%) | |
|---|---|---|
Number of patients | 15 (100) | 10 (100) |
Median age, years (range) | 44.1 (29–81) | 57.4 (40–91) |
≤50 | 8 (53.3) | 4 (40.0) |
>50 | 7 (46.7) | 6 (60.0) |
Menopausal status | ||
Pre | 8 (53.3) | 4 (40.0) |
Post | 7 (46.7) | 6 (60.0) |
Hormonal status | ||
Either ER+ or PgR+ | 8 (53.3) | 6 (60.0) |
ER−/PgR− | 7 (46.7) | 4 (40.0) |
Number of metastatic sites | ||
1 | – | 5 (50.0) |
≥2 | – | 5 (50.0) |
Metastatic sites | ||
Non visceral | – | 3 (30.0) |
Visceral* | – | 7 (70.0) |
Response to trastuzumab | ||
Complete response | 12 (80.0) | 3 (30.0) |
Partial response | 3 (20.0) | 4 (40.0) |
Stable disease | – | 3 (30.0) |